Weil advises Eli Lilly in its $1.1B acquisition of Dermira

Weil is advising Eli Lilly and Company in its pending $1.1 billion acquisition of Dermira, Inc., a developer of new therapies for chronic skin conditions. The transaction is expected to close in the first quarter of 2020 subject to customary closing conditions.

The Weil team advising Eli Lilly is led by Mergers & Acquisitions partners Raymond Gietz and Matthew Gilroy and includes Mergers & Acquisitions counsel Aileen Kim and Mergers & Acquisitions associates Sam Hulsey and Adena Kleiner (Not Yet Admitted in New York). The team also includes Tax partner Helyn Goldstein; Executive Compensation & Benefits partners Amy Rubin and Jennifer Haydel Britz; Technology & IP Transactions partner Jeffrey Osterman; Tax counsel Eric Remijan; Environmental counsel John O’Loughlin; Executive Compensation & Benefits associate Daniel Rios; and Technology & IP Transactions associates Kane Wishart and Caleb Small (Not Yet Admitted in New York).